Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
Abstract
We report spike protein-based lineage and AZD7442 (tixagevimab/cilgavimab) neutralizing activity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants identified from breakthrough infections in the PROVENT preexposure prophylaxis trial.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 06, 2023
- Source ID
- 10.1093/infdis/jiad210
Entities
People
- Anastasia A Aksyuk
- Andrew Ustianowski
- Bahar Ahani
- Elizabeth J. Kelly
- Gavin Koh
- Gustavo H. Kijak
- Jesse Thissen
- Katie Streicher
- Kevin M. Tuffy
- Miles Avila
- Myron J. Levin
- Nicolette Schuko
- Tianhui Zhang
- Tiffany L Roe
- Tyler Brady
Organizations
- AstraZeneca
- Federal Government of the United States
- North Manchester General Hospital
- United States Department of Defense
- United States Department of Health and Human Services
- University of Colorado School of Medicine